Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from thePharmaLetter

10:34 EDT 18th October 2017 | BioPortfolio

Here are the most relevant search results for "thePharmaLetter" found in our extensive news archives from over 250 global news sources.

More Information about thePharmaLetter on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about thePharmaLetter for you to read. Along with our medical data and news we also list thePharmaLetter Clinical Trials, which are updated daily. BioPortfolio also has a large database of thePharmaLetter Companies for you to search.

Showing News Articles 1–25 of 2,400+ from thePharmaLetter

Wednesday 18th October 2017

BRIEF—Priority review status for first PARP inhibitor application outside of ovarian cancer

The UK’s AstraZeneca and New Jersey-based Merck & Co have announced the US FDA will review an application…

As patent due to expire, AHF calls on Gilead for 90% price cut on tenofovir-based drugs

Noting that with the patent ending and generics looming, USA-based global AIDS organization AIDS Healthcare…

BRIEF—Novartis publishes positive long-term data in rare blood disorder

Switzerland’s Novartis has published long-term study safety and efficacy data from the EXTEND study…

Takeda starts production of anti-cancer drug in Russia

Takeda Pharmaceutical, together with Russia’s JSC Pharmstandard, announced the beginning of production…

BRIEF -- Latest QuintilesIMS Institute analysis on Orphan drugs

In the USA, the National Institutes for Health estimates that between 25 million and 30 million people…

BRIEF—Takeda in NASH deal with HemoShear

Takeda Pharmaceutical and privately-held US biotech HemoShear Therapeutics have announced a partnership…

Tuesday 17th October 2017

BRIEF—Latest Opdivo sBLA accepted by FDA

The US Food and Drug Administration (FDA) has accepted for priority review Bristol-Myers Squibb’s supplemental…

BRIEF—Entyvio analyses show improvements in ulcerative colitis or Crohn’s disease

Takeda Pharmaceutical has announced the presentation of data suggesting early symptomatic improvement…

Confirmed merger with Amneal sends Impax stock sliding

Shares in Impax Laboratories were worth 10% less at $18 after Tuesday morning’s trading.

Teva files potential blockbuster migraine drug for FDA approval

Teva Pharmaceutical Industries has submitted a Biologics License Application (BLA) to the US Food and…

Underlying economic data show drug prices are not soaring

While headlines tend to focus on high drug prices, particularly when price gouging is involved, the underlying…

Pfizer spin-off SpringWorks Therapeutics is an encouraging sign for innovation in big pharma

In this week's feature, Michael Jewell, the healthcare partner at Cavendish Corporate Finance, looks…

Promotion for new boy Riva at Gilead Sciences

Just a few months after joining the US biotech major, Alessandro Riva has received a promotion.

BRIEF --EMA publishes Business Continuity Plan for Brexit

The European Medicines Agency has published its Brexit Preparedness Business Continuity Plan. The plan,…

BRIEF—J&J’s quarter tops estimates

Presenting its latest quarterly results, US healthcare giant Johnson & Johnson posted adjusted earnings…

J&J jumps after pharma sales help to beat third-qtr estimates

Johnson & Johnson, the world’s largest healthcare company, looked set to open trading on Tuesday around…

Impact Biomedicines to resurrect abandoned myelofibrosis drug

US biotech start-up Impact Biomedicines announced its launch to pioneer the development of life-changing…

US District Court invalidates Restasis patents

The US District Court for the Eastern District of Texas has issued an adverse trial decision finding…

Around of half global pharma revenues comprised of MAb products, new report finds

The overall industry pipeline for monoclonal antibodies (MAbs) has reached an unprecedented scale, now…

Mutabilis joins European project supporting antiobiotics research

France's Mutabilis, a spinout from INSERM focused on new antibiotics, has announced it is participating…

Plasticell in deal with pharma major to produce hematopoietic cells from iPSCs

UK biotech Plasticell has entered into a collaboration with pharma major GlaxoSmithKline to use its combinatorial…

BRIEF—Impax and Amneal reportedly close to merger

Impax Laboratories and Amneal Pharmaceuticals are close to a merger agreement, The Wall Street reported…

FDA moves ahead with review of Imfinzi label expansion

AstraZeneca has announced that the US FDA has accepted its application to extend the marketable use of…

Helsinn Pharmaceuticals opens office in Shanghai

Swiss oncology specialist Helsinn has announced the expansion of its footprint in China, with the opening…

Monday 16th October 2017

Ipsen and Exelixis set for huge Cabometyx gains

Cabometyx (cabozantinib), a drug developed by US biotech Exelixis and French drugmaker Ipsen, is fast…


Quick Search
Advertisement
 

News Quicklinks